Cannvalate | Educational research centre

Cannvalate

Phone: +61 1300 633 226

Add/Update information

Reviews

Tags

• Businesses
• Medical and health
• Education
• Educational research centre

25.01.2022 Thank you to Mrityunjaya Das for leaving a review! Staff are very easy to deal with

25.01.2022 We are very proud to partner with MGC Pharmaceuticals. News of their increasing revenue with additional product orders for medicinal cannabis is very pleasing given we are one of their major distribution channels in Australia. Cannvalate continues to be Australias largest network of medicinal cannabis prescribing clinics with over 1,000 doctors and 600 pharmacies nationwide.

25.01.2022 Thank you to N E for leaving a review! Amazing staff and highly recommended! Thank you team!!!

25.01.2022 Thank you to June Magness for leaving a review! So much better when we can see Each Other....Was Easy To Use .... Thank you.

24.01.2022 A recent study has found Australians living with chronic pain face high rates of stigma and difficulty accessing affordable treatment. It was found more than 1 in 3 patients were restricted when accessing medicinal cannabis from GPs, due to a complicated approval process. Dr Sud Agarwal, CEO and cofounder, Cannvalate says "We hope our commitment to providing our network of over 1,000 prescribing doctors and pharmacies in Australia will better serve patient outcomes and help reduce these statistics. Article published today via The Sydney Morning Herald

24.01.2022 Congratulations to our friends and colleagues at, Impression Healthcare Limited, on the announcement of their exclusive supply agreement with AXIM Biotechnologies to supply toothpaste and mouthwash products containing cannabidiol (CBD) for the treatment of gum disease (periodontitis). We look forward to continuing our work with Impression, providing them with access to our network of over 1,000 prescribing doctors and pharmacies in Australia, as well as our clinical research trials for cannabidiol (CBD) containing dental products for severe periodontitis (gum disease).

24.01.2022 Thank you to Benjamin Peterson for leaving a review!

23.01.2022 Do you battle with bouts of insomnia and struggle to achieve a good night’s rest? The use of CBD oil is increasing at a rapid rate on a global scale and its calming properties have shown alleviation of sleep-related issues. To find out more details about whether CBD oil or other medicinal cannabis options may be the solution for you, book an appointment with one of our medical practitioners via the link in the bio. ... You’ll receive a FREE consultation to assess your eligibility and assistance on your road to a better night’s sleep. #medicinal #medicinalplants #medicinalcannabisaustralia #medicinalcannabis #cannvalate

23.01.2022 Thanks to Business News Australia for sharing the news of our recent distribution and logistics deal with MGC Pharmaceuticals, which will provide them with access to to our supply network and patients of medicinal cannabis prescribing clinics, consisting of more than 1,000 referring doctors and 600 affiliated pharmacies in all states across Australia.

23.01.2022 Thank you to Brad Davis for leaving a review! cannot rate this company enough ! What an easy transition from beginning to end.Very helpful and knowledgeable staff.

23.01.2022 Australia is at a turning point in its medicinal cannabis narrative. The question is not whether the industry will continue to grow, but by how much. Our CEO and Co-founder Dr Sud Agarwal shares his predictions for how the medicinal cannabis market is going to grow and change in terms of patient numbers, cultivation and employment before the end of the year.

23.01.2022 Dr Sud Agarwal, CEO and cofounder, Cannvalate joined Steve Darling from the Toronto studio of Proactive Investors to discuss Cannvalates plans to fast track its growth into the Australian and Canadian markets. Watch the full interview to hear the discussion which covered Cannvalates growing licensing and compliance, the clinical trials with The Swinburne University of Technology-Cannvalate Medicinal Cannabis Research Collaboration and plans to go public in 2019.

21.01.2022 Were thrilled to hear the news Althea Medicinal Cannabis is set to buy its way into Canadas emerging recreational cannabis market. Althea has agreed to terms to acquire Canadas Peak Processing Solutions and tapped into stockbroker PAC Partners to raise equity to help fund the acquisition. Dr Sud Agarwal, CEO and cofounder, Cannvalate says "Cannvalate continues to show its support for Althea and their high quality products and commitment to patient outcomes." Article published via Financial Review

21.01.2022 GW Pharmaceuticals has announced the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Epidyolex, for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy. If approved, the cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy. Dr Sud Agarwal, CEO and cofounder, Cannvalate says "Were thrilled to hear the news that the UK is progressing positively to improve patient access and outcomes in treating rare forms of epilepsy."

19.01.2022 Its been just over two years since medicinal cannabis was legalised in Australia, but since then the market has been growing exponentially, so much so that Australia is now the fourth largest market in the world. It is ripe with opportunity, however before Licensed Producers (LPs) make the leap, its important to understand a few differences between the Australian market and what they might be used to in Canada and the US. Here are a few points global LPs need to take into consideration before attempting to enter the Australian market.

19.01.2022 Many people associate medicinal cannabis with illicit drug users and imagine that most patients who seek out medicinal cannabis are simply looking for an easy way to obtain marijuana for recreational use. However there has been a big shift recently in how the medical profession views medicinal cannabis and its place in the health sector. Heres why they are starting to take it more seriously according to our CEO and cofounder, Dr. Sud Agarwal https://lnkd.in/gtjpbau

19.01.2022 Thank you to Walter Donney for leaving a review! I was extremely pleased with the way I was treated by the team at Cannvalate, they were curtious, knowledgeable and understanding of my health problems, and made it easy for me to obtain a consultation with their doctor. The doctor was also very helpful and polite, he explained the medication best for my health problems in terms I could easily understand. That was followed up by another member of the team that guided me through the remainder of the process. I was very pleased with the whole process. I can only hope the medication gives me the help I am looking for once I have tried it.

18.01.2022 Thank you to Di Turner for leaving a review!

18.01.2022 Another great write up about our new relationship with Impression Healthcare which will see Cannvalate conduct four clinical trials for the company via the Swinburne-Cannvalate Medicinal Cannabis Research Collaboration. The trials will test a synthetic cannabis treatment called dronabinol on obstructive sleep apnoea syndrome; a CBD chewing gum for gum disease; synthetic CBD oil on AFL and rugby players following concussion; and regular CBD oil on jaw joint dysfunction. Read more here

18.01.2022 Dr Sud Agarwal, CEO and cofounder, Cannvalate will be speaking at The Cannabis Societys Melbourne Investor Conference event, tomorrow, July 31. Dr Agarwal will be joining industry experts, entrepreneurs, Cannabis C-level investors and service providers for a Fireside chat, Q & A to discuss Medicinal Cannabis in the Australian market and investing opportunities. The event starts at 11 am. For tickets and event information follow the below link.

18.01.2022 "Dealing with Fibromyalgia pain? A study out of the Netherlands found that pharmaceutical-grade cannabis with a high tetrahydrocannabinol (THC) content was effective in treating the musculoskeletal pain caused by fibromyalgia. Learn more about this study here via @TheGrowthOp: Visit: https://bit.ly/2WNpLGw

17.01.2022 Canadians and Australians both have a keen interest in complementary and alternative therapies such as massage, acupuncture and naturopathy. An estimated two out of three Australians have used alternative medicine, while 79% of Canadians report having tried complementary therapies at some point in their lives. With Australia legalising medicinal cannabis in 2016, the growth trajectory of medicinal cannabis users that weve seen so far in Australia is very similar to what was seen in Canada in the early days of commercial legalisation. Our CEO Dr Sud Agarwal here shares four reasons why keeping an eye on Canada can help us predict whats next for Australia.

17.01.2022 Thank you to Alex Longworth for leaving a review!

17.01.2022 A great video by MedMen Help us change the perception

17.01.2022 Thank you to Sylvia E. Berjas-Morales for leaving a review!

15.01.2022 When it comes to getting the best in care that’s affordable, trustworthy, and discreet, Cannvalate ticks all the boxes. Our network of experienced cannabinoid prescribers are fully licenced with the requisite expertise, ensuring total peace of mind no matter your health concerns. #medicinal #medicinalplants #medicinalcannabisaustralia #medicinalcannabis #cannvalate

15.01.2022 Find out more about her incredible story and how we were able to help her access a legal, effective and affordable medicinal cannabis solution.

15.01.2022 We welcome the recent announcement that the European Parliament Passed a Cannabis Resolution and Joined WHO In Supporting Medical Marijuana. Read more here via Forbes Javier Hasse https://lnkd.in/fRzQP9S... s See more

14.01.2022 Allowing medicinal cannabis research in the USA could open the floodgates to the creation of novel cannabinoid drugs - this is a massive paradigm shift for the medical cannabis industry. We are proud to say that Cannvalate is already operating Australias first cannabis-dedicated research department via the Swinburne-Cannvalate Medicinal Cannabis Research Collaboration (MCRC) with trials under way for both Impression Healthcare and MGC Pharma.

13.01.2022 Thank you to Ken Glover for leaving a review! Fantastic service quickly easy helpful supportiveThank you

13.01.2022 Thank you to Kubilay Mulayim for leaving a review! It was a pleasure talking with them, really great customer service. The turn around time from when I first contacted them till receiving the product was really quick and everything was handled really professionally and quickly, especially by Jonathan who really went above and beyond. I have seen good changes in my grandmothers alzheimers condition, so thank you all at Cannvalate!

13.01.2022 The Cannvalate team are excited to welcome, Andrew Gaudry, who will lead our Canadian operation, educating and guiding Canadian Licensed Producers (LPs) on how they can access our turnkey solutions for accelerating their access into the Australian market including, cultivation, medical market access, clinical research and compliance & listing.

13.01.2022 "This is an outcome we can truly stand behind! In an unprecedented ruling, two Australian parents were released of criminal drug charges for giving medical cannabis to their autistic son. I accept that theres no evidence that the child Callum was injured. I accept that you provided the drug to him for medicinal purposes and after receiving medical advice. And as [your] counsel have said, your offending comes through altruistic objectives, that is, youre trying to take care of your child. That law may well be changed next year, and it is, then, of course, you would access the medical treatment that is allowable by law to assist your son as any father would.Visit: https://bit.ly/2HZx8qO

10.01.2022 Thank you to Sam Tamei for leaving a review! Great customer service. Mainly dealt with Mr Peters who kept things precise and simple enough for me. Cheerio guys

10.01.2022 Thank you to Ritchie Wise for leaving a review! Outstanding service.. The entire team were very helpful. The advice, guidence and support through the process was fantastic. I would have no hesitation with recommending them to help get the best assistance.. Thank you so much Cannvalate

10.01.2022 Congratulations to Althea Medicinal Cannabis who have achieved the 1,000 patient milestone, five months ahead of schedule. Dr Sud Agarwal, CEO and cofounder, Cannvalate says "The Cannvalate medical prescribers have voted to show their support for AGH and their high quality products and commitment to patient outcomes."

09.01.2022 Cannvalate is committed to advancing the Australian cannabis industry with exceptional quality products. The Valens Company have an unmatched track record in Canada and the Cannvalate team are proud to introduce them to the Australian market. https://www.cannvalate.com.au/australias-biggest-medicinal/

09.01.2022 London is emerging as the European hub for cannabis companies looking to raise money, as a second business plans a stock market listing in the coming months. European Cannabis Holdings, which helped to secure the arrival of the first legal marijuana shipment in Britain last week, has hired Canaccord Genuity to drum up investors. It is understood to be eyeing a valuation of more than 100m. Read more here https://www.thetimes.co.uk//european-cannabis-holdings-hir

09.01.2022 Thank you to Robert Goodwin for leaving a review!

09.01.2022 Dr Sud Agarwal, CEO and cofounder, Cannvalate recently had the opportunity to speak at the World Cannabis Congress (WCC), held on June 16-18 in Canada. He joined cannabis leaders from around the world to spark conversation and enlist change, while providing insights into the Australian medicinal cannabis industry and the importance to fast track Cannvalates growth into market.

08.01.2022 As part of the United In Compassion Conference in Tweed Heads, New South Wales this week, we will be hosting an EXCLUSIVE, Executive C-Suite Lunch on Sunday 24 March, where we will share case studies of Licensed Producers (LPs) who we have helped successfully: - Capture large subsections of the Australian medicinal cannabis marketplace - Secure clinical trials to create compelling evidence for prescribers - Get their cultivation programs up and running with minimal equity a...nd time LIMITED SPOTS AVAILABLE - Please contact us to reserve your seat and find out how we can help accelerate your progress into the Australian market, with turnkey solutions for: - Cultivation - Medical Market Access - Clinical Research - Compliance and Licensing EMAIL TO SECURE YOUR SPOT [email protected]

08.01.2022 Congratulations to our colleagues at Impression Healthcare Limited on the announcement of their supply agreement with Myoderm North America for Dronabinol to use in a clinical trial for sleep apnoea. Dr Sud Agarwal, CEO and cofounder, Cannvalate says "We look forward to continuing our work with Impression, providing them with access to our network of over 1,000 prescribing doctors and pharmacies in Australia and will continue to show our support for IHL and their commitment to patient outcomes."

08.01.2022 Aphria Announces Conclusion of Special Committee Review Read more here via https://www.newcannabisventures.com/aphria-special-committ/

08.01.2022 We are delighted to announce that we are now representing MGC Pharmas product range across Australia. Their product range is carefully crafted and has been well received by the medical community. We are also supporting them to initiate a number of clinical trials at the Swinburne University of Technology-Cannvalate, Medicinal Cannabis Research Collaboration. The outcome of these trials will lead to increased confidence across the medical community as physicians will be able to draw on local data specific to MGC Pharmas product range.

07.01.2022 In 2014-15 an estimated 1.2 million Australians over the age of 18 had diabetes. Studies note that the anti-inflammatory capabilities of the cannabinoids in marijuana may have therapeutic effects that may help to: stabilize blood sugar, lower blood pressure, prevent nerve inflammation, and improve circulation in diabetics. Visit: https://bit.ly/2SHDMX8

07.01.2022 "Myrcene is one of the most common terpenes found in cannabis. This molecule produces an earthy, spicy, clove fragrance in the strains which is dominates. Its medical effects? Myrcene is a sedative in nature, meaning relaxed muscles and a reduction of pain." Visit: https://bit.ly/2E8I15N

06.01.2022 In Australia, the use of medicinal cannabis was decriminalised in 2016. In the past year, the number of prescriptions has grown by 800%. With usage on the rise and so much hype in the media, there is still alot of misinformation. In this article, our CEO and co-founder Dr Sud Agarwal looks at separating the myths from the facts.

05.01.2022 Another life changed through expert medical advice and personalised treatment plans. We have testimonials from so many satisfied patients who have experienced an improved quality of life through our services. Experience the Cannvalate difference by getting in touch today... #medicinalcannabisaustralia #medicinalcannabis #cannvalate.

03.01.2022 We are excited to announce that we now working with Impression Healthcare to perform game-changing clinical research for significant medical diseases at our world class, Swinburne University of Technology-Cannvalate medicinal cannabis research collaboration, Australias first, cannabis-only Contract Research Organisation. "Researching cannabinoid pharmacological solutions for obstructive sleep apnoea, periodontitis, traumatic brain injury and TMJ dysfunction is particularly exciting as all four of these diseases have no existing therapies available today," said CEO and cofounder, Cannvalate, Dr Sud Agarwal.

03.01.2022 Thank you to always annonymous for leaving a review!

02.01.2022 Thank you to Thegreenfund for their article announcing the news of Cannvalates CEO and cofounder, Dr Sud Agarwals recent appointment as the Chief Medical Officer for Impression Healthcare along with a role as a non executive director on their medical advisory board. Dr Sud Agarwal says "Im thrilled to continue this exciting partnership of our two companies and to streamline the clinical trials on behalf of IHL to progress medicinal cannabis products and open new markets, via the Swinburne-Cannvalate medicinal cannabis research collaboration."

01.01.2022 A new report from a cannabis industry analyst firm based in Washington, D.C., New Frontier Data, argues that Latin American cannabis is well-positioned to be a big player in the global cannabis industry and that it is already on the way . The report states that 13 million of the 600 million people in Latin America use cannabis at least one a year and estimates the total market value of cannabis in Latin America, both legal and illicit, to be worth $9.8 billion . Read more via link here https://cannabisnow.com/latin-american-cannabis-market-wor/

01.01.2022 "Cannabis activism is for all ages! This 13 year old has struggled with a rare condition for half of her life, but thanks to medical cannabis, things have gotten significantly better for her over the last five years. Now, shes fighting to help other young children get access to the potentially life-saving benefits of cannabis. Story via @civilized.life https://www.civilized.life//a-rare-disease-turned-this-13/"

01.01.2022 What is medicinal cannabis and how does it differ from other products purchased online? Find out more about the regulatory structure behind medicinal cannabis and the system that is designed to ensure patients are provided with medication that meets strict quality and consistency guidelines. visit: https://www.cannvalate.com.au/

01.01.2022 Thank you to John Hall for leaving a review!